Liquid Biopsies - The Clinics and the Molecules

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

KUBACZKOVÁ Veronika SEDLAŘÍKOVÁ Lenka BOLLOVÁ Božena SANDECKÁ Viera ŠTORK Martin POUR Luděk ŠEVČÍKOVÁ Sabina

Year of publication 2017
Type Article in Periodical
Magazine / Source Klinická onkologie
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.14735/amko20172S13
Field Oncology and hematology
Keywords cell-free DNA non-coding RNA; liquid biopsies; minimal residual disease; multiple myeloma
Description Unlike bone marrow bio psies, liquid bio psies represent a gentler, more accessible, less painful,repeatable and more comprehensive approach to get bio logically relevant information about the entire tumor but also about treatment response and level of minimal residual disease. This is all possible since peripheral blood contains not only circulating tumor cells but also many circulating molecules of nucleic acids (microRNA, cell-free DNA, long non-coding RNA etc.).Multiple myeloma is a genetically heterogeneous disease characterized by multifocal tumor deposits in the bone marrow but also focal lesions elsewhere. Single-site bio psy of the bone marrow creates a sampling bias that provides a limited molecular profile as the bio psy cannot capture all subclones. Moreover, during disease progression and treatment, molecular profile is changed and subclones of multiple myeloma cells resistant to treatment are formed. Likewise,various clones found in extramedullary sites that are not present in the bone marrow respond differently to treatment directly influencing survival of patients. Thus, liquid bio psies seem to be a relevant and necessary next step for diseases such as multiple myeloma.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.